T. Rowe Price Investment Management, Inc. Xenon Pharmaceuticals Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 76,943 shares of XENE stock, worth $2.97 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76,943
Previous 796,986
90.35%
Holding current value
$2.97 Million
Previous $26.7 Million
90.99%
% of portfolio
0.0%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding XENE
# of Institutions
221Shares Held
73.2MCall Options Held
336KPut Options Held
309K-
Avoro Capital Advisors LLC New York, NY5.4MShares$209 Million3.08% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.34MShares$168 Million1.31% of portfolio
-
Braidwell LP Stamford, CT3.61MShares$139 Million6.91% of portfolio
-
Janus Henderson Group PLC London, X03.58MShares$138 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA3.18MShares$123 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.41B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...